#USA #New York #Pomerantz LLP #SEC Investigation #Celcuity Inc.

Investor Alert: Pomerantz Law Firm Questions Celcuity Inc.

In a significant move for investors in Celcuity Inc. (NASDAQ: CELC), Pomerantz LLP has initiated an investigation aimed at uncovering potential securities fraud and unlawful practices involving the company and its officers or directors. As the focus on corporate governance heightens in the wake of various scandals, this inquiry stands to impact many stakeholders.

On July 14, 2026, Celcuity announced that it had received approval from the U.S. Food and Drug Administration (FDA) for its promising breast cancer therapy, Revtorpyk (gedatolisib). While this was anticipated news for many, the company's guidance regarding the commercial launch timeline raised concerns. Celcuity indicated a launch in late third quarter of 2026, which diverged from prior market expectations and has led analysts to express skepticism. Analyst Stephen Wiley of Stifel remarked that this launch window appears overly extended, while Leerink’s Andrew Berens noted that the timing was unexpected given previous comments on launch readiness.

The immediate fallout from the announcement was palpable, with Celcuity's stock plummeting by $19.54, a staggering 17.6%, resulting in a closing price of $91.51 per share on July 15, 2026. This market reaction highlights the volatility that can accompany corporate announcements, particularly those concerning pivotal product launches.

Pomerantz LLP, with a storied legacy in securities class action litigation, aims to protect investors' rights amid these troubling indicators. Founded over 85 years ago by Abraham L. Pomerantz, often referred to as one of the pioneers of class action lawsuits, the firm has a strong track record of fighting against securities fraud and has orchestrated numerous successful recoveries for its clients.

For investors potentially affected by the uncertain dynamics surrounding Celcuity, the opportunity to participate in the upcoming class action is on the table. Pomerantz encourages any investors with pertinent information or concerns regarding Celcuity to reach out directly to Danielle Peyton at 646-581-9980, ext. 7980, or via email at [email protected]. It’s crucial for those involved to stay informed and engaged, especially given the unfolding scrutiny over corporate behavior.

As this investigation draws more attention, the implications of the recent developments at Celcuity will likely be closely monitored not only by investors but also by analysts and market observers. With the potential ramifications of the investigation weighing heavily, stakeholders are advised to keep a pulse on this evolving story.

In conclusion, Pomerantz LLP's investigation into Celcuity underscores the ongoing commitment of legal entities to uphold the integrity of financial markets and protect the interests of investors. By shedding light on potential malpractices, firms like Pomerantz serve a vital function in fortifying investor confidence and promoting accountability in corporate America.